CRL · Charles River Laboratories International, Inc.
Price & Indicators
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Diagnostics & Research — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CRL
this stock
Charles River Laboratories International, Inc.
|
$13.77B | +44.6% | +10.5% | — | 4.9% |
|
TMO
Thermo Fisher Scientific Inc.
|
$226.94B | +5.9% | +14.5% | 33.0 | 1.3% |
|
DHR
Danaher Corp /De/
|
$145.98B | -9.3% | +8.5% | 36.8 | 1.2% |
|
NTRA
Natera, Inc.
|
$47.31B | +43.3% | -2.8% | — | 3.0% |
|
IQV
Iqvia Holdings Inc.
|
$44.69B | +18.8% | +41.6% | 33.3 | 2.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CRL | -1.0% | +7.9% | +89.8% | +0.1% | +44.6% |
| SPY | +0.1% | -0.4% | +15.1% | +0.4% | +12.9% |
| vs SPY | -1.1% | +8.3% | +74.7% | -0.3% | +31.7% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.